Literature DB >> 10368453

Inhalation of low-dose nitric oxide to evaluate pulmonary vascular reactivity in children with congenital heart disease.

T Yasuda1, N Tauchi, R Baba, K Nishibata, T Hatano, S Nakamura, M Nagashima.   

Abstract

The objective of this study was to investigate the efficacy of low-dose nitric oxide (NO). The study used fifteen consecutive Japanese preoperative patients (7 males and 8 females) with congenital heart disease and pulmonary hyptertension (mean pulmonary arterial pressure >30 mmHg), 6 of these patients had Down's syndrome. Hemodynamic measurements were taken in room air, 100% oxygen, 5 and 40 parts per million NO (NO5 and NO40) by inhalation. The differences between two observations within the same group were determined by the two-tailed paired t-test. A pulmonary vascular resistance (Rp) regression curve was constructed by using linear regression analysis. The percentage change in pulmonary arterial pressure per systemic arterial pressure (Pp/Ps) with NO40 (Pp/Ps-40) exceeded that of Pp/Ps-5 (p < 0.0001). The percentage change for the Rp with NO40 (Rp-40) was larger than that for the Rp-5 (p = 0.0003). The percentage change of Pp/Ps-5 and that with oxygen were similar (p = 0.266). The relationship between Rp-5 and Rp-40 was linear. In conclusion, the effects of NO5 were equivalent to 100% oxygen but less than NO40. NO5 should initially be used to test pulmonary reactivity. If there is no response, patients should still be given NO40.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368453     DOI: 10.1007/s002469900463

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  2 in total

1.  From PediHeart: inhaled nitric oxide-references

Authors: 
Journal:  Pediatr Cardiol       Date:  2000-05       Impact factor: 1.655

Review 2.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.